Schneeweiss A, Michel LL, Mobus V, Tesch H, et al. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast Eur J Cancer 2021 Nov 17. pii: S0959-8049(21)01164.
PMID: 34801353